Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
This study was designed as a non-interventional observational study. Kaletra was prescribed in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients ≥ 18years of age
Written informed consent (authorization to the investigator to use and/or disclose personal and/or health data before entry into the KALETRA® post marketing observational study)
HIV-1 infection
Patients treated with KALETRA®, independent from their participation in this study
Patients treated with novel antiretroviral therapy (for at least 8 weeks according to the study amendment), independent from their participation in this study
You may not be if
Hypersensitivity against Kaletra or other ingredients or INIs or NNRTIs or CCR5 antagonists
Severe liver insufficiency
No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and/or St. John's wort
